Compare ENGN & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENGN | ANIX |
|---|---|---|
| Founded | 1999 | 1982 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.2M | 103.9M |
| IPO Year | 2023 | 2013 |
| Metric | ENGN | ANIX |
|---|---|---|
| Price | $1.95 | $2.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | $4.29 | ★ $9.67 |
| AVG Volume (30 Days) | ★ 1.5M | 183.7K |
| Earning Date | 12-21-2026 | 09-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 56.85 | 12.82 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $210,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.40 | $2.32 |
| 52 Week High | $12.25 | $5.46 |
| Indicator | ENGN | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 55.31 | 38.28 |
| Support Level | $1.61 | $2.51 |
| Resistance Level | $8.93 | $3.09 |
| Average True Range (ATR) | 0.18 | 0.21 |
| MACD | 0.07 | -0.06 |
| Stochastic Oscillator | 47.17 | 3.34 |
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.